TESAMORELIN 5/10mg
£50.00
(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY)
Tesamorelin (brand names Egrifta SV, Egrifta WR)
is a synthetic peptide and growth hormone-releasing hormone (GHRH) analogue. It is primarily used to stimulate the pituitary gland to release endogenous growth hormone.
FDA Approval and Medical Use
- Approved Indication: Tesamorelin is the only FDA-approved medication specifically indicated to reduce excess visceral abdominal fat in adults with HIV who have lipodystrophy (an abnormal distribution of body fat).
- Mechanism: It works by increasing the natural production of growth hormone, which helps decrease deep fat stored around the organs.
- Not for General Weight Loss: It is not approved for general weight loss or the treatment of obesity in non-HIV patients.
Administration and Dosage
- Method: Administered as a daily subcutaneous injection, typically in the abdominal area.
- Standard Dose: The recommended clinical dose is 2 mg once daily.
- Formulations: It comes as a lyophilized powder that must be reconstituted with a diluent before use. New formulations like Egrifta WR (approved in March 2025) require weekly reconstitution instead of daily.
Potential Benefits (Off-Label & Research)
Beyond its primary use, tesamorelin is studied for various metabolic and physical benefits:
- Visceral Fat Reduction: Highly effective at targeting deep abdominal fat that is resistant to diet and exercise.
- Cognitive Health: Some research investigates its potential to improve cognitive function in older adults or those with mild cognitive impairment.
- Metabolic Improvement: It is being evaluated for treating insulin resistance and non-alcoholic fatty liver disease (NAFLD).
Safety and Side Effects
Common side effects are generally mild but can include:
- Local Reactions: Redness, itching, or pain at the injection site.